Autologous NK cell treatment for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a personalized immune treatment made from your own NK cells (a type of blood-fighting immune cell) for relapsed or refractory B-cell non-Hodgkin lymphoma. It aims to check safety and whether the treatment can shrink lymphoma and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 80 years old, and you’re expected to live more than 6 months
- Your non-Hodgkin B-cell lymphoma diagnosis is confirmed by pathology within the last 3 years
- Your lymphoma is newly classified as relapsed or refractory as your first time in this situation
- You can do day-to-day activities fairly well (ECOG 0–2)
- You have at least one measurable lymphoma spot on CT that’s at least 1.5 cm
- If you could become pregnant (or father a child), you must use pregnancy testing and reliable birth control rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hear when a new NK Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.